WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of…
Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to…
Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to…
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s…
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s…
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all…
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all…
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or…
Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years. Results suggest…
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Scientists developed an antibody treatment that…